Elezanumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AE12-1Y-QL; ABT-555 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.